Wealthfront Inc. Increases Holdings in Zoetis Inc. (ZTS)
Wealthfront Inc. boosted its position in Zoetis Inc. (NYSE:ZTS) by 3.3% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 14,409 shares of the company’s stock after purchasing an additional 456 shares during the period. Wealthfront Inc.’s holdings in Zoetis were worth $899,000 as of its most recent SEC filing.
A number of other large investors have also recently made changes to their positions in ZTS. CGOV Asset Management boosted its position in Zoetis by 2.7% in the first quarter. CGOV Asset Management now owns 169,605 shares of the company’s stock worth $12,059,000 after purchasing an additional 4,405 shares during the last quarter. UBS Asset Management Americas Inc. boosted its position in Zoetis by 5.0% in the first quarter. UBS Asset Management Americas Inc. now owns 1,942,609 shares of the company’s stock worth $103,677,000 after purchasing an additional 91,962 shares during the last quarter. Coyle Financial Counsel LLC boosted its position in Zoetis by 3.9% in the first quarter. Coyle Financial Counsel LLC now owns 18,298 shares of the company’s stock worth $977,000 after purchasing an additional 686 shares during the last quarter. Ameriprise Financial Inc. boosted its position in Zoetis by 21.1% in the first quarter. Ameriprise Financial Inc. now owns 1,614,416 shares of the company’s stock worth $86,167,000 after purchasing an additional 281,139 shares during the last quarter. Finally, Toronto Dominion Bank boosted its position in Zoetis by 277.6% in the first quarter. Toronto Dominion Bank now owns 132,558 shares of the company’s stock worth $7,074,000 after purchasing an additional 97,455 shares during the last quarter. 93.20% of the stock is currently owned by institutional investors and hedge funds.
Shares of Zoetis Inc. (NYSE ZTS) traded up 0.26% during mid-day trading on Thursday, reaching $64.65. The company had a trading volume of 335,216 shares. The stock has a 50 day moving average of $62.44 and a 200-day moving average of $59.64. Zoetis Inc. has a 52 week low of $46.86 and a 52 week high of $65.83. The company has a market capitalization of $31.62 billion, a price-to-earnings ratio of 36.55 and a beta of 1.02.
Zoetis (NYSE:ZTS) last issued its quarterly earnings results on Tuesday, August 8th. The company reported $0.53 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.53. The company had revenue of $1.27 billion for the quarter, compared to the consensus estimate of $1.27 billion. Zoetis had a return on equity of 62.49% and a net margin of 17.50%. Zoetis’s revenue for the quarter was up 5.0% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.49 earnings per share. On average, analysts expect that Zoetis Inc. will post $2.34 earnings per share for the current fiscal year.
Several research analysts have issued reports on ZTS shares. Cantor Fitzgerald set a $75.00 target price on Zoetis and gave the stock a “buy” rating in a research report on Monday, August 14th. Stifel Nicolaus reissued a “buy” rating and issued a $65.00 target price on shares of Zoetis in a research report on Friday, September 1st. Argus reissued a “buy” rating and issued a $69.00 target price (up from $60.00) on shares of Zoetis in a research report on Tuesday, May 30th. CL King started coverage on Zoetis in a research report on Friday, May 26th. They issued a “buy” rating and a $71.00 target price on the stock. Finally, Deutsche Bank AG reissued a “buy” rating and issued a $65.00 target price (up from $62.00) on shares of Zoetis in a research report on Monday, July 17th. One analyst has rated the stock with a sell rating, five have issued a hold rating and thirteen have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average target price of $65.44.
Zoetis Company Profile
Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.
Receive News & Ratings for Zoetis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.